The exploration of macrocycles for drug discovery — an underexploited structural class
暂无分享,去创建一个
Stephen P. Hale | E. Driggers | S. Hale | N. Terrett | Jinbo Lee | Jinbo Lee | Edward M. Driggers | Nicholas K. Terrett
[1] Marilyn A. Anderson,et al. Discovery of Cyclotide-Like Protein Sequences in Graminaceous Crop Plants: Ancestral Precursors of Circular Proteins?[W] , 2006, The Plant Cell Online.
[2] Pravin Chaturvedi,et al. Design principles for orally bioavailable drugs , 1996 .
[3] R. Gussio,et al. Comparison of the Activities of the Truncated Halichondrin B Analog NSC 707389 (E7389) with Those of the Parent Compound and a Proposed Binding Site on Tubulin , 2006, Molecular Pharmacology.
[4] S. Beauchemin,et al. Discovery of a new class of macrocyclic antagonists to the human motilin receptor. , 2006, Journal of medicinal chemistry.
[5] M. Faul,et al. (S)-13-[(dimethylamino)methyl]-10,11,14,15-tetrahydro-4,9:16, 21-dimetheno-1H, 13H-dibenzo[e,k]pyrrolo[3,4-h][1,4,13]oxadiazacyclohexadecene-1,3(2H)-d ione (LY333531) and related analogues: isozyme selective inhibitors of protein kinase C beta. , 1996, Journal of medicinal chemistry.
[6] J. Sanglier,et al. Antascomicins A, B, C, D and E. Novel FKBP12 binding compounds from a Micromonospora strain. , 1996, The Journal of antibiotics.
[7] D. Pei,et al. Macrocyclic inhibitors for peptide deformylase: a structure-activity relationship study of the ring size. , 2004, Journal of medicinal chemistry.
[8] M. Spaller,et al. Bridged peptide macrocycles as ligands for PDZ domain proteins. , 2005, Organic letters.
[9] William Fenical,et al. Species-Specific Secondary Metabolite Production in Marine Actinomycetes of the Genus Salinispora , 2006, Applied and Environmental Microbiology.
[10] S. Schreiber,et al. Macrolactones in diversity-oriented synthesis: preparation of a pilot library and exploration of factors controlling macrocyclization. , 2004, Journal of combinatorial chemistry.
[11] E. Katz,et al. The peptide antibiotics of Bacillus: chemistry, biogenesis, and possible functions. , 1977, Bacteriological reviews.
[12] S. Matthews,et al. Resisting degradation by human elastase: commonality of design features shared by 'canonical' plant and bacterial macrocyclic protease inhibitor scaffolds. , 2007, Bioorganic & medicinal chemistry.
[13] M. Katharine Holloway,et al. Macrocyclic Inhibitors of β-Secretase: Functional Activity in an Animal Model. , 2006 .
[14] Hatsuo Aoki,et al. FK-506, a novel immunosuppressant isolated from a Streptomyces. I. Fermentation, isolation, and physico-chemical and biological characteristics. , 1987 .
[15] W. Greenlee,et al. Macrocyclic renin inhibitors : synthesis of a subnanomolar, orally active cysteine derived inhibitor , 1993 .
[16] K. Giuliano,et al. Tubulin assembly, taxoid site binding, and cellular effects of the microtubule-stabilizing agent dictyostatin. , 2005, Biochemistry.
[17] J. Clardy. Structural studies on FK-506, cyclosporin A and their immunophilin complexes , 1994 .
[18] W. DeGrado,et al. Template-Constrained Cyclic Peptides: Design of High-Affinity Ligands for GPIIb/IIIa , 1994 .
[19] Ronald J Quinn,et al. A common protein fold topology shared by flavonoid biosynthetic enzymes and therapeutic targets. , 2006, Journal of natural products.
[20] B. Brandhuber,et al. 750 Preclinical characteristics of ITMN-B, an orally active inhibitor of the HCV NS3/4A protease nominated for preclinical development , 2006 .
[21] R A Stearns,et al. Highly potent, orally active diester macrocyclic human renin inhibitors. , 1992, Journal of medicinal chemistry.
[22] S. Schreiber,et al. STRUCTURAL BASIS FOR PEPTIDOMIMICRY BY A NATURAL PRODUCT , 1994 .
[23] P. Ruggli. Über einen Ring mit dreifacher Bindung , 1912 .
[24] L. Wessjohann. Synthesis of natural-product-based compound libraries. , 2000, Current opinion in chemical biology.
[25] Matthew P Jacobson,et al. Conformational flexibility, internal hydrogen bonding, and passive membrane permeability: successful in silico prediction of the relative permeabilities of cyclic peptides. , 2006, Journal of the American Chemical Society.
[26] E. Nogales,et al. Structure of tubulin at 6.5 Å and location of the taxol-binding site , 1995, Nature.
[27] David J Newman,et al. Natural products as sources of new drugs over the period 1981-2002. , 2003, Journal of natural products.
[28] Derek S. Tan,et al. Exploiting ligand conformation in selective inhibition of non-ribosomal peptide synthetase amino acid adenylation with designed macrocyclic small molecules. , 2007, Journal of the American Chemical Society.
[29] L. Wessjohann,et al. What Can a Chemist Learn from Nature′s Macrocycles? A Brief, Conceptual View , 2005 .
[30] Bruce E Maryanoff. Inhibitors of serine proteases as potential therapeutic agents: the road from thrombin to tryptase to cathepsin G. , 2004, Journal of medicinal chemistry.
[31] Chang Park,et al. Structure-based design, synthesis, and biological evaluation of potent and selective macrocyclic checkpoint kinase 1 inhibitors. , 2007, Journal of medicinal chemistry.
[32] Douglas A. Horton,et al. Difficult macrocyclizations: new strategies for synthesizing highly strained cyclic tetrapeptides. , 2003, Organic letters.
[33] D. Fairlie,et al. Synthesis, stability, antiviral activity, and protease-bound structures of substrate-mimicking constrained macrocyclic inhibitors of HIV-1 protease. , 2000, Journal of medicinal chemistry.
[34] Martin Poirier,et al. Structure-activity study on a novel series of macrocyclic inhibitors of the hepatitis C virus NS3 protease leading to the discovery of BILN 2061. , 2004, Journal of medicinal chemistry.
[35] H. Briem,et al. Macrocyclic Aminopyrimidines as Multitarget CDK and VEGF‐R Inhibitors with Potent Antiproliferative Activities , 2007, ChemMedChem.
[36] Martin J Scanlon,et al. Conformationally constrained macrocycles that mimic tripeptide beta-strands in water and aprotic solvents. , 2002, Journal of the American Chemical Society.
[37] F. Schluenzen,et al. Structural basis for the interaction of antibiotics with the peptidyl transferase centre in eubacteria , 2001, Nature.
[38] T. Nicas,et al. Mechanism of action of oritavancin and related glycopeptide antibiotics. , 2003, FEMS microbiology reviews.
[39] J. Nielsen,et al. Combinatorial synthesis of natural products. , 2002, Current opinion in chemical biology.
[40] Y. Kook,et al. Phylogenetic analysis of the genera Streptomyces and Kitasatospora based on partial RNA polymerase beta-subunit gene (rpoB) sequences. , 2004, International journal of systematic and evolutionary microbiology.
[41] D. Williams,et al. Why are secondary metabolites (natural products) biosynthesized? , 1989, Journal of natural products.
[42] A. Krantz,et al. Synthesis and activity of conformationally-constrained macrocyclic norstatine-based inhibitors of HIV protease , 1996 .
[43] G. Kroemer,et al. Current development of mTOR inhibitors as anticancer agents , 2006, Nature Reviews Drug Discovery.
[44] A. Kwong,et al. Preclinical Profile of VX-950, a Potent, Selective, and Orally Bioavailable Inhibitor of Hepatitis C Virus NS3-4A Serine Protease , 2006, Antimicrobial Agents and Chemotherapy.
[45] B. Maryanoff,et al. Macrocyclic inhibitors of serine proteases , 1997 .
[46] C. Verlinde,et al. Structure-based design of a macrocyclic inhibitor for peptide deformylase. , 2003, Journal of medicinal chemistry.
[47] S. Schreiber,et al. Synthesis and analysis of 506BD, a high-affinity ligand for the immunophilin FKBP , 1991 .
[48] Mark S Butler,et al. Natural products to drugs: natural product derived compounds in clinical trials. , 2005, Natural product reports.
[49] Paul H. Axelsen,et al. Simultaneous Recognition of a Carboxylate-Containing Ligand and an Intramolecular Surrogate Ligand in the Crystal Structure of an Asymmetric Vancomycin Dimer , 1997 .
[50] L. Wessjohann,et al. Strategies for Total and Diversity-Oriented Synthesis of Natural Product(-like) Macrocycles , 2005 .
[51] P. Bonneau,et al. An NS 3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus , 2003 .
[52] L. Wessjohann,et al. Macrocycles Rapidly Produced by Multiple Multicomponent Reactions Including Bifunctional Building Blocks (MiBs) , 2005 .
[53] Arun K. Ghosh,et al. Synergistic Effects of Peloruside A and Laulimalide with Taxoid Site Drugs, but Not with Each Other, on Tubulin Assembly , 2006, Molecular Pharmacology.
[54] D. Williams,et al. On the evolution of functional secondary metabolites (natural products) , 1992, Molecular microbiology.
[55] H. Hirai,et al. Structure-based drug design of a highly potent CDK1,2,4,6 inhibitor with novel macrocyclic quinoxalin-2-one structure. , 2006, Bioorganic & medicinal chemistry letters.
[56] W. DeGrado,et al. Macrocyclic amino carboxylates as selective MMP-8 inhibitors. , 1998, Journal of medicinal chemistry.
[57] A. Gradillas,et al. Macrocyclization by ring-closing metathesis in the total synthesis of natural products: reaction conditions and limitations. , 2006, Angewandte Chemie.
[58] Terry Walsh,et al. Countering cooperative effects in protease inhibitors using constrained beta-strand-mimicking templates in focused combinatorial libraries. , 2004, Journal of medicinal chemistry.
[59] R. Hughes,et al. Solid- and solution-phase synthesis of vancomycin and vancomycin analogues with activity against vancomycin-resistant bacteria. , 2001, Chemistry.
[60] William Fenical,et al. Genome sequencing reveals complex secondary metabolome in the marine actinomycete Salinispora tropica , 2007, Proceedings of the National Academy of Sciences.
[61] J. Blondeau. The evolution and role of macrolides in infectious diseases , 2002, Expert opinion on pharmacotherapy.
[62] K. Altmann,et al. Epothilones as lead structures for the synthesis-based discovery of new chemotypes for microtubule stabilization. , 2008, Accounts of chemical research.
[63] Amitha K. Hewavitharana,et al. Discovery of a New Source of Rifamycin Antibiotics in Marine Sponge Actinobacteria by Phylogenetic Prediction , 2006, Applied and Environmental Microbiology.
[64] R. Hughes,et al. Synthesis and biological evaluation of vancomycin dimers with potent activity against vancomycin-resistant bacteria: target-accelerated combinatorial synthesis. , 2001, Chemistry.
[65] Herbert Waldmann,et al. From protein domains to drug candidates-natural products as guiding principles in the design and synthesis of compound libraries. , 2002, Angewandte Chemie.
[66] R J Lynch,et al. Design and synthesis of P2-P1'-linked macrocyclic human renin inhibitors. , 1991, Journal of medicinal chemistry.
[67] P. Wender,et al. The design, computer modeling, solution structure, and biological evaluation of synthetic analogs of bryostatin 1. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[68] Herbert Waldmann,et al. From protein domains to drug candidates – natural products as guiding principles in , 2002 .
[69] A L Demain,et al. The natural functions of secondary metabolites. , 2000, Advances in biochemical engineering/biotechnology.
[70] Steven R. LaPlante,et al. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus , 2003, Nature.
[71] F. Lombardo,et al. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. , 2001, Advanced drug delivery reviews.
[72] Paul A Clemons,et al. Relationship of stereochemical and skeletal diversity of small molecules to cellular measurement space. , 2004, Journal of the American Chemical Society.
[73] D. Rich,et al. Peptidomimetics derived from natural products , 1993, Medicinal research reviews.
[74] Dajun Yang,et al. A novel macrocyclic tetrapeptide mimetic that exhibits low-picomolar Grb2 SH2 domain-binding affinity. , 2003, Biochemical and biophysical research communications.
[75] Andrew G. Leach,et al. Comparison of the ATP binding sites of protein kinases using conformationally diverse bisindolylmaleimides. , 2005, Journal of the American Chemical Society.
[76] A. Krantz,et al. Design, synthesis, and activity of conformationally-constrained macrocyclic peptide-based inhibitors of HIV protease , 1994 .
[77] S. Matsunaga,et al. Bioactive marine metabolites. 33. Cyclotheonamides, potent thrombin inhibitors, from a marine sponge Theonella sp , 1990 .
[78] R J Lynch,et al. Renin inhibitors containing conformationally restricted P1-P1' dipeptide mimetics. , 1991, Journal of medicinal chemistry.
[79] D. Pei,et al. High-throughput synthesis and screening of cyclic peptide antibiotics. , 2007, Journal of medicinal chemistry.
[80] S. Schreiber,et al. The mechanism of action of cyclosporin A and FK506. , 1992, Immunology today.
[81] É. Marsault,et al. Potent macrocyclic antagonists to the motilin receptor presenting novel unnatural amino acids. , 2007, Bioorganic & medicinal chemistry letters.
[82] Måns Ehrenberg,et al. The mechanism of action of macrolides, lincosamides and streptogramin B reveals the nascent peptide exit path in the ribosome. , 2003, Journal of molecular biology.
[83] Stuart L. Schreiber,et al. Structure of the FKBP12-Rapamycin Complex Interacting with Binding Domain of Human FRAP , 1996, Science.
[84] David R. Liu,et al. DNA-Templated Organic Synthesis and Selection of a Library of Macrocycles , 2004, Science.
[85] B. Podlogar,et al. Design, synthesis, and conformational analysis of a novel macrocyclic HIV-protease inhibitor. , 1994, Journal of medicinal chemistry.
[86] K. Stankunas,et al. Rapamycin analogs with differential binding specificity permit orthogonal control of protein activity. , 2006, Chemistry & biology.
[87] Rolf Müller,et al. Evolutionary implications of bacterial polyketide synthases. , 2005, Molecular biology and evolution.
[88] Matthew P Jacobson,et al. Testing the conformational hypothesis of passive membrane permeability using synthetic cyclic peptide diastereomers. , 2006, Journal of the American Chemical Society.
[89] J. Huff,et al. Conformational restriction of flexible ligands guided by the transferred noe experiment: potent macrocyclic inhibitors of farnesyltransferase. , 2001, Journal of the American Chemical Society.
[90] F. Koehn,et al. The evolving role of natural products in drug discovery , 2005, Nature Reviews Drug Discovery.
[91] P. Bonneau,et al. Macrocyclic inhibitors of the NS3 protease as potential therapeutic agents of hepatitis C virus infection. , 2003, Angewandte Chemie.
[92] P. Nghiem,et al. Tacrolimus and pimecrolimus: from clever prokaryotes to inhibiting calcineurin and treating atopic dermatitis. , 2002, Journal of the American Academy of Dermatology.
[93] S. Schreiber. Immunophilin-sensitive protein phosphatase action in cell signaling pathways , 1992, Cell.
[94] Wim J. N. Meester,et al. Intramolecular Staudinger ligation: a powerful ring-closure method to form medium-sized lactams. , 2003, Angewandte Chemie.
[95] N. Matsumori,et al. Amphotericin B covalent dimers forming sterol-dependent ion-permeable membrane channels. , 2002, Journal of the American Chemical Society.
[96] Dajun Yang,et al. Development of a phosphatase-stable phosphotyrosyl mimetic suitably protected for the synthesis of high-affinity Grb2 SH2 domain-binding ligands. , 2002, Bioorganic & medicinal chemistry letters.
[97] H. Ye,et al. Novel bis(indolyl)maleimide pyridinophanes that are potent, selective inhibitors of glycogen synthase kinase-3. , 2007, Bioorganic & medicinal chemistry letters.
[98] A. D. Rodrigues,et al. 3-Aminopyrrolidinone farnesyltransferase inhibitors: design of macrocyclic compounds with improved pharmacokinetics and excellent cell potency. , 2002, Journal of medicinal chemistry.
[99] Dudley H. Williams,et al. The Vancomycin Group of Antibiotics and the Fight Against Resistant Bacteria , 1999 .